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Familial hypercholesterolemia (FH) is characterised by elevated serum levels of low-density lipoprotein 
cholesterol (LDL-C) and a substantial risk for cardiovascular disease. The autosomal-dominant FH 
is mostly caused by mutations in LDLR (low density lipoprotein receptor), APOB (apolipoprotein B), 
and PCSK9 (proprotein convertase subtilisin/kexin). Recently, STAP1 has been suggested as a fourth 
causative gene. We analyzed STAP1 in 75 hypercholesterolemic patients from Berlin, Germany, who 
are negative for mutations in canonical FH genes. In 10 patients with negative family history, we 
additionally screened for disease causing variants in LDLRAP1 (low density lipoprotein receptor adaptor 
protein 1), associated with autosomal-recessive hypercholesterolemia. We identified one STAP1 variant 
predicted to be disease causing. to evaluate association of serum lipid levels and STAP1 carrier status, 
we analyzed 20 individuals from a population based cohort, the Cooperative Health Research in South 
Tyrol (CHRIS) study, carrying rare STAP1 variants. Out of the same cohort we randomly selected 100 
non-carriers as control. In the Berlin FH cohort STAP1 variants were rare. In the CHRIS cohort, we 
obtained no statistically significant differences between carriers and non-carriers of STAP1 variants 
with respect to lipid traits. Until such an association has been verified in more individuals with genetic 
variants in STAP1, we cannot estimate whether STAP1 generally is a causative gene for fH.
Autosomal-dominant hypercholesterolemia (FH, OMIM 143890) is one of the most common genetic disorders, 
characterised by severely elevated levels of low-density lipoprotein cholesterol (LDL-C). Its estimated preva-
lence ranges between 1:500 and 1:2501–3. Patients with FH are at substantial risk of developing atherosclerotic 
plaque deposition leading to premature coronary artery disease (CAD) or other cardiovascular disease (CVD)4. 
Diagnosis of FH is established clinically by pronounced hypercholesterolemia, xanthomas and corneal arcus, as 
well as history of premature CAD, other CVD, or other features suggestive of FH in the individual and first degree 
family members. On a molecular level, diagnosis of FH can be confirmed by presence of a heterozygous patho-
genic mutation in one of three genes: LDLR (low density lipoprotein receptor, OMIM 606945)5,6, APOB (apolipo-
protein B, OMIM 107730)7,8 and PCSK9 (proprotein convertase subtilisin/ kexin, OMIM 607786)9. In some cases 
homozygosity, compound heterozygosity within the same gene, and double-heterozygotes for mutations in two of 
these genes can be observed10. Moreover, mutations in LDLRAP1 (low density lipoprotein receptor adaptor pro-
tein, OMIM 605747) have been associated with familial hypercholesterolemia inherited in an autosomal-recessive 
manner (ARH, OMIM 603813)11,12.These patients can be treated by LDL-apheresis13 and PCSK9 inhibition with 
evolocumab in addition to statin and ezetimibe treatment14,15.
In FH patients, early diagnosis is essential for improvement of prognosis, reduction of cardiovascular mor-
tality, and prevention of cardiovascular events by dietary and medical treatment. Clinically pre-diagnosed FH 
patients, e.g. based on the Dutch Lipid Clinic Network criteria (DLCNC)16,17, should undergo DNA testing which 
is an effective way to confirm diagnosis in an index patient and to cascade-screen families to identify other rela-
tives with FH at risk for early CVD. Our working group has recently published data on the mutational spectrum 
in the genes LDLR, APOB, and PCSK9 in 206 FH patients from Germany18. However, in our clinics, DNA testing 
of the three canonical FH genes was negative in approximately 60%, which is in the range reported by others19. 
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Therefore, further research is necessary to identify new causative genes and to verify proposed candidate genes in 
independent cohorts to improve the molecular genetic diagnosis in FH patients who have not yet been confirmed 
by molecular genetic testing.
STAP1 (signal transducing adaptor family member 1, OMIM 604298) encodes a docking protein also known 
as BRDG1 (BCR downstream signaling-1), which acts downstream of TEC (TEC protein tyrosine kinase) in 
B-cell antigen receptor signaling20. Using family-based linkage analysis in combination with whole exome 
sequencing in FH patients from the Netherlands, STAP1 has been recently suggested to be the fourth FH gene21. 
However, the molecular mechanism by which STAP1 is supposed to act on cholesterol homeostasis remains 
unexplained.
This study represents a systematic molecular genetic analysis of STAP1 in 75 unresolved FH patients, here 
defined as the Berlin FH cohort. In a separate, population-based cohort we evaluated association of carrier status 
for rare STAP1 variants with total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density 
lipoprotein cholesterol (HDL-C), and triglycerides (TG), since LDL-C levels have previously been postulated to 
be significantly higher in carriers of rare STAP1 variants compared to wild type21.
Materials and Methods
The Berlin FH cohort. We included a total of 75 unrelated patients, who were diagnosed between 2012 and 
2017 in the specialized Lipid Clinic at the Interdisciplinary Metabolism Centre, Charité - Universitätsmedizin 
Berlin, Germany, and who were initially screened negative for mutations in canonical FH genes (LDLR, APOB, 
PCSK9)18. Clinical diagnosis of FH was established as described previously18. In brief, we took the lipid parame-
ters total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides (TG), and lipopro-
tein a [Lp(a)] as well as patients’ anamnesis, family history and physical examination into account. Additionally, 
we calculated a score according to the Dutch Lipid Clinic Network criteria (DLCNC)16,17, where a score >8 
stands for “definite”, 6–8 for “probable”, 3–5 for “possible”, and <3 for “unlikely” diagnosis of FH. DLCN score 
calculation was not obligatory to enter genetic testing. LDL-C levels were compared to those obtained from 1600 
older adults (age range 60–80 years) of Berlin Aging Study II (BASE-II)19,22 serving as the basic population and 
from patients with molecularly confirmed FH18. In patients receiving lipid lowering medication, we calculated 
medication-naïve LDL-C using conversion factors as described previously18.
Mutation screening. Genomic DNA was extracted from peripheral blood by standard procedures. We per-
formed Sanger sequencing of all 9 exons of STAP1 (NM_012108) including flanking intronic sequences. In 10 
patients with negative family history we additionally analyzed the 9 exons and flanking intronic sequence of 
LDLRAP1 (NM_015627). Obtained sequences were analyzed using the Genious 9.1 software. Identified variants 
were checked using the database of the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/), 
the Human Gene Mutation Database (HGMD) and evaluated using PolyPhen23 and Mutation Taster24.
Association of STAP1 variants with lipid parameters in a population based cohort. To ana-
lyze the association of lipid parameters with carrier status of rare STAP1 variants, we defined 20 participants 
of the Cooperative Health Research in South Tyrol (CHRIS) study carrying rare STAP1 variants (ExAC minor 
allele frequency, MAF < 0.002) that were predicted to be disease-causing by MutationTaster as carriers. Further 
100 participants of the CHRIS study were randomly selected as controls, i.e. non-carriers. Genetic analyses in 
this cohort were previously performed using Illumina HumanOmniExpressExome Bead Chip, which includes 
~250,000 exonic variants25.
Human subject recruitment, experimental procedures and research. Written informed con-
sent was obtained from all participants. The Charité studies were approved by the ethics committee of the 
Charité – Universitätsmedizin Berlin, approval numbers EA2/089/14 and EA2/029/09; the CHRIS study was 
approved by the ethical committee of the Healthcare System of the Autonomous Province of Bolzano (Südtiroler 
Sanitätsbetrieb/Azienda Sanitaria dell’Alto Adige), protocol no. 21/2011. All experimental procedures and 
research was performed in accordance with relevant guidelines/regulations.
Data analysis. Statistical analyses were performed using the IBM Statistical Package for the Social Sciences 
version 22.0 (IBM SPSS Statistics for Windows, Armonk, NY: IMB Corp. USA). Graphics were created using 
GraphPad Prism 6. Data from CHRIS study participants were additionally analyzed and plotted using R. 
P-values < 0.05 were considered to indicate statistical significance.
Results
Berlin FH cohort - Clinical characteristics. Characteristics and assessed lipid parameters are summarized 
in Table 1. Patients were admitted based on one of the following criteria or a combination of them: clinical signs 
of hyperlipidemia such as xanthomata and arcus lipoides, abnormality of lipid parameters, and positive family 
history of cardiovascular disease. Based on DLCN scores, diagnosis of FH was definite (>8) in five, probable 
(6-8) in 13, and possible (3–5) in 48 patients. In further nine, the score was <3. The latter patients were still 
included in the current study since moderately elevated lipid levels have been reported in association with STAP1 
variants21. 64% were female and 36% were male. Except for HDL-C, lipid parameters did not significantly differ 
between males and females (Supplementary Fig. S1). The median age was 55 years. TC and LDL-C levels tended 
to be higher at higher age (Supplementary Fig. S2). As shown in Fig. 1, LDL-C levels of the Berlin FH cohort were 
significantly higher when compared to data from a population based BASE-II cohort. However, the levels were 
significantly lower when compared to confirmed FH patients with known mutations in LDLR and APOB (each 
p < 0.001).
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Berlin FH cohort - Sequencing results. In all 75 patients sequencing analysis revealed no deleteri-
ous mutation in STAP1, i.e. nonsense or frameshift-mutations. All three identified variants within the coding 
sequence are listed in Supplementary Table S1. Despite two variants predicted to be benign, we identified one 
individual carrying a rare single nucleotide variant (SNV), rs199787258, with an estimated MAF of 0.0003 
(ExAC). This STAP1 variant, c.526 C > T, p.(Pro176Ser) was described as disease-causing mutation in the Online 
Table III by Fourier and colleagues21 and recently by Blanco-Vaca and coworkers26. In the Berlin FH cohort, 
the 78-year-old male patient carrying this variant presented with abnormal lipid parameters: elevated TC of 





   Mean ± SD 53 ± 13
   Range 25–81
TC in mg/dl
   Median (IQR) 313 (272–344)
   Range 190–677
LDL-C in mg/dl
   Median (IQR) 223 (199–247)
   Range 88–456
HDL-C in mg/dl
   Median (IQR) 58 (51–69)
   Range 30–117
TG in mg/dl
   Median (IQR) 175 (125–261)
   Range 45–1127
DLCN-Score Interpretation Number of individuals
   <3 Unlikely FH 09
   3–5 Possible FH 48
   6–8 Probable FH 13
   >8 Definite FH 05
Table 1. Characteristics of the Berlin FH cohort. The table displays sex, age, and lipid parameters (TC, total 
cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglycerides) as well as calculated 
DLCN (Dutch Lipid Clinic Network criteria) score and its distribution. IQR, interquartile Range.
Figure 1. LDL-C serum level according to the mutation status of the genes LDLR, APOB, and PCSK9. LDL-C 
serum concentrations (mg/dl) are shown for a population based cohort (BASE-II, N = 1631)). LDL-C serum 
concentrations of the hypercholesterolemic patients with respect to the mutation status in one of the three FH 
genes LDLR, APOB, PCSK9 (mutation negative (N = 75) vs. mutation found (N = 68)). Black lines indicate 
medians and dots single values. One-way ANOVA revealed significant differences between groups (p < 0.001). 
Post hoc Tukey’s test revealed significant differences between all possible pairs with ***indicating p < 0.001.
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450 mg/dl (reference <200 mg/dl), elevated LDL-C of 360 mg/dl (reference <130 mg/dl), HDL-C of 68 mg/dl 
(reference >55 mg/dl), elevated TG of 222 mg/dl (reference <200 mg/dl), and Lp(a) of 190 mg/l (reference 
<300 mg/l). Segregation within the family revealed that his 49-years old son carried the same variant with follow-
ing lipid parameters: elevated TC of 270 mg/dl, elevated LDL-C of 159 mg/dl, reduced HDL-C of 26 mg/dl, and 
elevated TG of 498 mg/dl. Unfortunately, no other relatives were available for the segregation study. Sequencing 
of LDLRAP1 coding sequence in the 10 patients with negative family history to exclude autosomal-recessive 
hypercholesterolemia (ARH) revealed no pathogenic variant.
CHRIS cohort - lipid parameters in carriers of rare STAP1 variants. To gain further insights into 
the association of rare STAP1 variants with abnormal lipid parameters, we therefore tested for association in 
an independent, population-based cohort, the Cooperative Health Research in South Tyrol (CHRIS) study25. 
Characteristics of the STAP1 variants identified in 20 participants, here defined as ‘carriers’ of the CHRIS cohort, 
are summarized in Table 2. Of note, one of them carried the same STAP1 variant (rs199787258, c.526 C > T, 
p.Pro176Ser) that we had observed in the Berlin FH cohort, suddenly associated with almost normal lipid 
parameters at the age of 54 years: TC 206 mg/dl (reference TC <200 mg/dl), LDL-C 111 mg/dl (reference LDL-C 
<115 mg/dl), HDL-C 82 mg/dl (reference HDL-C in females >45 mg/dl), and TG 81 mg/dl (reference TG 
30–150 mg/dl).
For further analyses, we randomly selected 100 CHRIS study participants in whom rare STAP1 variants, 
i.e. MAF <0.002, were excluded, to characterize the distribution of the lipid parameters and termed them 
‘non-carriers’.
Visualization of the lipid parameters (Fig. 2) revealed that lipid values TC and LDL-C of the individual from 
the Berlin FH cohort were higher than values of the individuals of the CHRIS cohort, no matter whether they 
were carriers or non-carriers. The values of the son of the index patient of the Berlin FH cohort carrying the 
same variant were within the distribution of non-carriers of the CHRIS cohort. In contrast to LDL-C, one of the 
key parameters used to establish the diagnosis of FH, we observed TG levels comparable to the Berlin FH index 
patient both in some carriers and some non-carriers.
We also tested the hypothesis that carriers of a rare variant in STAP1 have higher lipid parameters using 
an unpaired two-sided Mann-Whitney U test. However, no statistically significant differences were observed 
(Supplementary Table S2, Supplementary Fig. S3). Additionally, we raised the question whether abnormality of 
lipid levels taken as a categorical variable might be more frequent in carriers versus non-carriers. Although we 
observed a marginal preponderance of elevated TC levels, a slight preponderance of normal (!) LDL-C levels, a 
slight preponderance of elevated TG levels, and a slight preponderance of reduced HDL-C levels in carriers, none 
of these differences revealed statistical significance (Supplementary Table S3, Supplementary Fig. S4).
Finally, we excluded that confounders such as sex or age might have blurred association. Of the CHRIS study 
participants included into these analyses, 67 were females and 53 were males. Sex ratio in STAP1 variant carriers 
was nine males to 11 females, i.e. 45% versus 55%, and in non-carriers 44 males to 56 females, i.e. 44% versus 
56%. Except for HDL-C, lipid parameters did not significantly differ between males and females (Supplementary 
Fig. S5). Median age was 48 years in all participants, 55 years in carriers, and 47 years in non-carriers. Higher 
TC as well as higher LDL-C were associated with higher age (each p < 0.001), and TG slightly increased with 
increasing age (p < 0.05) (Supplementary Fig. S6). In summary, sex distribution can be excluded as a confounder, 
and the age structure would lead to false positive but not false negative results, if at all. Additionally, linear regres-
sion analyses with lipid parameters as dependent variables and adjusting for sex, age and carrier status (yes/no) 
revealed no significant differences in lipid levels between carriers and non-carriers (data not shown).
Discussion
Based on family studies and next-generation sequencing (NGS), three genes in addition to the established FH 
genes were identified, in which mutations may be causing significantly elevated LDL-C levels and possibly the 
clinical phenotype of FH: STAP1 (signal transducing adaptor protein family 1), LIPA (lysosomal acid lipase) and 
PNPLA5 (patatin-like phospholipase-domain-containing family)21,27,28. To our knowledge, confirmation of the 




(hg19) A1 A2 MAF
DNA 
changes AA changes Mutation taster PolyPhen
Number of carriers 
(total n = 20)
rs146545610 4:68449380 G A 0.0001 c.619 G > A p.Asp207Asn disease causing benign 3
rs141647540 4:68424562 G A 0.0002 c.35 G > A p.Arg12His disease causing probably damaging 14
rs149803575 4:68447073 G C 0.0017 c.414 G > C No changes disease causing benign 2
rs199787258 4:68447185 C T 0.0003 c.526 C > T p.Pro176Ser disease causing probably damaging 1
Table 2. Rare STAP1 variants observed in the CHRIS cohort. Given are the dbSNP IDs, chromosomal 
coordinates according to human genome GRCh37 (hg19), the effective allele A1, the alternative allele A2 on 
the forward strand, the minor allele frequency (MAF), the change on DNA level where position 1 of the “c” 
coordinate is the A of the ATG start (NM_012108). AA changes describes the estimated change on amino 
acid level, and the columns MutationTaster and PolyPhen give the prediction of the corresponding tools. The 
last column indicates the number of individuals carrying the distinct variant. Note, that the STAP1-variant 
rs199787258 was also identified in two individuals of the Berlin FH cohort.
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Since allocation to the Berlin FH cohort is based on abnormal lipid parameters, association of a genetic var-
iant with elevated lipid parameters in this cohort could be biased. Further, segregation of the identified STAP1 
variant c.526 C > T, p.(Pro176Ser) in two first degree relatives can be observed by chance in 50%, and segregation 
within families can also be biased since individuals from the same families do not only share genetic traits but 
may additionally share environment, culture, and habits. The segregation study of this variant within the family 
described by Blanco-Vaca and coworkers also indicates a polygenic contribution to hypercholesterolemia. There, 
the daughter of the index patient, who also carried the c.526 C > T, p.(Pro176Ser) variant, had no hypercholester-
olemia, in contrast to her brother, who as a non-carrier showed the phenotype26. Taken together, both previous 
findings and findings in our cohort cannot clarify whether the identified STAP1 variant is incidental or causative 
for the observed phenotype.
Genome wide association studies such as the one by Teslovich et al.29 suggested 95 loci for blood lipids. 
However, they obtained no hit for STAP1 alias BRDG1. The linkage interval on chromosome 4p15.1-q13.3 (hg19; 
chr4:27,700,001-76,300,000) obtained by Fouchier et al. encompasses 48.6 Mb21. Comparison of both studies 
revealed that the genes KLHL8 and SLC39A8 are the only candidate genes having an impact on lipid traits local-
ized on chromosome 4. However, both are localized outside the linkage interval. Thus, we cannot exclude that 
there might be yet another candidate gene for FH hidden within this linkage interval which might also segregate 
with the observed phenotype.
Paquette and colleagues used genetic risk scores (GRSs) to evaluate the polygenetic modification of FH phe-
notype30. This approach included 13 common SNPs on chromosome 4 of which two, rs17087335 in NOA1, and 
rs10857147 (between PRDM8 and FGF5) are localized within the linkage interval described by Fouchier and 
colleagues. However, there was no informative common SNP in STAP1.
Figure 2. Lipid values according to STAP1 variant carrier status. For carriers of rare STAP1 variants 
[rs14655610 (N = 3), rs141647540 (N = 14), rs14983575 (N = 2), and rs199787258 (N = 1)], as well as STAP1 
non-carriers (N = 100) individual values of (A) Total cholesterol (TC), (B) LDL-cholesterol (LDL-C), (C) 
Triglycerides (TG), and (D) HDL cholesterol (HDL-C) are depicted. Colored dots indicate values of participants 
of the CHRIS study, i.e. 20 carriers and 100 non-carriers. Bars indicate median values. To allow for comparison, 
black triangles indicate values of the two individuals of the Berlin FH cohort. Since these individuals originate 
from a different cohort and were assessed in a different laboratory, calculation of a median is not applicable for 
rs199787258.
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Pirillo et al. used exome screening in an Italian cohort of FH patients where they confirmed diagnosis in 67% 
by molecular genetic analysis. They used a DLCN score >5 as inclusion criterion31. Since Fouchier and colleagues 
suggested that mutations in STAP1 are associated with less severe elevation of lipid parameters, we did not use 
such a stringent DLCN score cut-off in our study. Thus, the expected mutation detection rate should be lower in 
comparison to the one reported by Pirillo and colleagues31.
If one takes all patients with hypercholesterolemia or lipid lowering medication into account, one would 
expect to detect causative mutations in one of the known FH genes in 2.1% and 2.2% of cases, respectively32.
The frequency of rare STAP1 variants predicted to be pathogenic or possibly pathogenic in the FH4 
cohort of Fouchier et al. was 1.3% (5 of 400 individuals). We identified one carrier in 75 unrelated individuals 
(1/75 = 1.3%)21. Thus, our study on the Berlin FH cohort confirms that STAP1 variants are fairly rare.
It might be possible that a substantial number of the unresolved cases in the Berlin FH cohort carry a single 
mutation in one of the known or unknown FH genes that cannot be detected by conventional methods. It is a lim-
itation of our study, that we have not evaluated polygenic FH variants such as the APOE rs429358 systematically 
or screened for mutations in this gene, as these were shown to be associated with hypercholesterolemia33–35. The 
use of a less stringent DLCN cut-off might also lead to inclusion of a significant fraction of patients with poly-
genic hypercholesterolemia (PHC). Here, affected individuals carry a greater-than-average number of common 
cholesterol-raising genetic variants that collectively have a detectable effect on LDL-C levels36. Additionally, one 
might even speculate that epigenetic DNA modifications caused by in utero exposure to hypercholesterolemia 
might influence LDL-C levels and possibly the clinical phenotype of FH. Indeed, there are differentially meth-
ylated regions that are associated with serum LDL cholesterol, and DNA methylation signatures link prenatal 
malnutrition to growth and adverse metabolic phenotype in the offspring37. We note, that 10/75 individuals, i.e. 
13% of the (unresolved) Berlin FH cohort were born between 1936 and 1950.
The participants of the CHRIS study were assigned to carrier and control groups based on the presence or 
absence of one of the rare variants in STAP1 (MAF <0.002). Thus, we cannot exclude presence of other rare 
variants in STAP1 in members of the control group such as deep intronic or enhancer variants that cannot be 
captured by the genotyping strategy used in the CHRIS study.
Our statistical analysis contains the uncertainty that lipid lowering medication might have blurred association 
between STAP1 variants and lipid parameters. However, only six of the 120 selected participants have stated that 
they take lipid lowering medication. Thus, we assume, that this will probably have no substantial effect on our 
result.
Another limitation of our study is the limited number of carriers of identical STAP1 variants. Since statistical 
significance is dependent on sample size, we pooled four different rare SNPs in STAP1 to obtain a sample size 
of at least 5. In contrast, Fouchier and colleagues performed segregation of large numbers of carriers versus 
non-carriers within families resulting in rather homogeneous subgroups. Thus, distinct variants within these 
families are associated with abnormal lipid parameters and the large sample size can give significance even for 
slight differences.
Genetic sequencing analyses are commonly used not only to confirm the diagnosis, but also to identify other 
family members at risk of cardiovascular disease. The elevation of lipid parameters associated with pathogenic 
variants in STAP1 is rather mild in comparison to pathogenic variants in the canonical FH genes LDLR, APOB, 
and PCSK9. In addition, our study revealed that at least in the Berlin FH cohort, rare sequence variants that 
might be pathogenic and deleterious mutations are not common. Thus, we conclude that the positive predictive 
value of STAP1 analysis will be comparably small. Based on our data, we can therefore not postulate that STAP1 
analysis has necessarily to be included into molecular assessment of cardiovascular risk by sequencing panels. 
However, further knowledge about STAP1 sequence variants in FH patients could help to estimate whether spe-
cific domains in this gene might be associated with a higher risk to develop FH, or whether rare genetic variants 
in STAP1 may modify the disease phenotype of FH. Further work, including in vitro functional studies, should 
focus on the molecular interactions of STAP1 to verify the role in pathogenesis of FH.
The next step will be retrospective analysis of APOE33, LIPA and PNPLA527 in the Berlin FH cohort, since 
mutations in these genes may cause significantly elevated LDL-C levels and possibly the clinical phenotype of 
FH. Additionally, determination of the 6 SNPs score described by Futema34 and colleagues in the Berlin cohort 
would be helpful to further delineate the genetic bases of LDL-C levels in this cohort. In prospective studies on 
FH patients, exome sequencing combined with more stringent inclusion criteria might be reasonable.
Data Availability
Due to concerns for participant privacy, data are available only upon request. External scientists may apply to the 
internal committee of the study of interest (CHRIS or BASE-II) for data access.
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